UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 311

Sortiert nach

Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people

Immunity & ageing, 2008-07, Vol.5 (1), p.6-6, Article 6

2008

Volltextzugriff (PDF)

Immunosenescence and Cytomegalovirus: where do we stand after a decade?

Immunity & ageing, 2010-09, Vol.7 (1), p.13-13, Article 13

2010

Volltextzugriff (PDF)

Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]

Vaccine: X, 2023-08, Vol.14, p.100307-100307, Article 100307

2023

Volltextzugriff (PDF)

How to approximate users’ values while preserving privacy: experiences with using attitudes towards work tasks as proxies for personal value elicitation

Ethics and information technology, 2013-03, Vol.15 (1), p.45-61

2013

Volltextzugriff (PDF)

Self-adjuvanted RNActive® vaccine induces local immune responses at the injection site leading to potent adaptive immunity in mice and humans

Journal for immunotherapy of cancer, 2014-11, Vol.2 (S3), p.P172-P172, Article P172

2014

Volltextzugriff (PDF)

Effects of Shareholder Groups on the Factoring Institutions Profitability: Evidence from Germany

International journal of economics and finance, 2015-10, Vol.7 (11), p.39

Koch, Sven

2015

Volltextzugriff (PDF)

A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive®-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part

Journal for immunotherapy of cancer, 2014-11, Vol.2 (Suppl 3), p.P85-P85

2014

Volltextzugriff (PDF)

Fine-trading vs. reverse factoring: external financing and optimal working capital ratios

Corporate finance: Finanzmanagement, bewertung, kapitalmarkt, mergers & acquisitions, 2014-01, Vol.16 (11), p.460-469

Koch, Sven

2014

Volltextzugriff (PDF)

A large multicenter, randomized, double-blind, crossover study in healthy volunteers, comparing pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar pegfilgrastim with European and United States reference pegfilgrastim

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e23118-e23118

2019

Volltextzugriff (PDF)

Abstract 2161: Identifying GDF-15 as potential novel immunotherapeutic target linked to immune cell exclusion in tumors and resistance to anti-PD-1 treatment

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.2161-2161

2020

Volltextzugriff (PDF)

Cytomegalovirus Infection

Annals of the New York Academy of Sciences, 2007-10, Vol.1114 (1), p.23-35

2007

Volltextzugriff (PDF)

NKp80 defines and stimulates a reactive subset of CD8 T cells

Blood, 2009-01, Vol.113 (2), p.358-369

2009

Volltextzugriff (PDF)

RNAdjuvant®, a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile

The Journal of immunology (1950), 2017-05, Vol.198 (1_Supplement), p.79-79.7

2017

Volltextzugriff (PDF)

P3.02c-091 Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1333-S1334

2017

Volltextzugriff (PDF)

P3.02c-091 Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC: Topic: IT Clinical

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1333-S1334

2017

Volltextzugriff (PDF)

Identification of two early differentiated populations within CD4+ and CD8+ TEMRA T‐cells

The FASEB journal, 2008-03, Vol.22 (S1)

2008

Volltextzugriff (PDF)

Investigating the influence of personal values on requirements for health care information systems

Proceedings of the 3rd Workshop on Software Engineering in Health Care, 2011, p.48-55

2011

Volltextzugriff (PDF)

Messenger RNA vaccination and B-cell responses in NSCLC patients

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.2573-2573

2012

Volltextzugriff (PDF)

RNAdjuvant®, a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile

Journal for immunotherapy of cancer, 2015-11, Vol.3 (Suppl 2), p.P163-P163

2015

Volltextzugriff (PDF)

A novel, disruptive vaccination technology: Self-adjuvanted RNActive

Human vaccines & immunotherapeutics, 2013-06, Vol.9 (10), p.2263-2276

2013

Volltextzugriff (PDF)

Human cytomegalovims infection and T cell immunosenescence : A mini review

Mechanisms of ageing and development, 2006, Vol.127 (6), p.538-543

2006

Volltextzugriff (PDF)

Cytomegalovirus infection: a driving force in human T cell immunosenescence

Annals of the New York Academy of Sciences, 2007 (1114), p.23

2007

Volltextzugriff (PDF)

Layoutplanung

Fabrikplanung, 2021, p.409-454

2021

Volltextzugriff (PDF)

Gebäudeplanung und Technische Gebäudeausrüstung

Fabrikplanung, 2021, p.455-495

2021

Volltextzugriff (PDF)

Integrated information display to support ICU nurses at the bedside: Ethnographic observation, design, and evaluation

Koch, Sven Heinrich

2010

Volltextzugriff (PDF)

1 – 25 von 311

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(239)
Mit Volltextzugriff
(277)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(271)
Deutsch
(42)
Japanisch
(14)
Norwegisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(91)
Physical Sciences
(39)
Technology
(39)
Humans
(28)
Science & Technology - Other Topics
(25)
Chemistry
(23)
Multidisciplinary Sciences
(22)
Engineering
(21)
Animals
(20)
Male
(19)
Female
(17)
Physics
(16)
Biological And Medical Sciences
(15)
Computer Science
(12)
Social Sciences
(12)
Medical Sciences
(11)
Patients
(11)
Calcium
(10)
Mortality
(10)
Natural Sciences
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people

Immunosenescence and Cytomegalovirus: where do we stand after a decade?

Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]

How to approximate users’ values while preserving privacy: experiences with using attitudes towards work tasks as proxies for personal value elicitation

Self-adjuvanted RNActive® vaccine induces local immune responses at the injection site leading to potent adaptive immunity in mice and humans

Effects of Shareholder Groups on the Factoring Institutions Profitability: Evidence from Germany

A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive®-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part

Fine-trading vs. reverse factoring: external financing and optimal working capital ratios

A large multicenter, randomized, double-blind, crossover study in healthy volunteers, comparing pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar pegfilgrastim with European and United States reference pegfilgrastim

Abstract 2161: Identifying GDF-15 as potential novel immunotherapeutic target linked to immune cell exclusion in tumors and resistance to anti-PD-1 treatment

Cytomegalovirus Infection

NKp80 defines and stimulates a reactive subset of CD8 T cells

RNAdjuvant®, a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile

P3.02c-091 Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC

P3.02c-091 Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC: Topic: IT Clinical

Identification of two early differentiated populations within CD4+ and CD8+ TEMRA T‐cells

Investigating the influence of personal values on requirements for health care information systems

Messenger RNA vaccination and B-cell responses in NSCLC patients

RNAdjuvant®, a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile

A novel, disruptive vaccination technology: Self-adjuvanted RNActive

Human cytomegalovims infection and T cell immunosenescence : A mini review

Cytomegalovirus infection: a driving force in human T cell immunosenescence

Layoutplanung

Gebäudeplanung und Technische Gebäudeausrüstung

Integrated information display to support ICU nurses at the bedside: Ethnographic observation, design, and evaluation

Aktive Filter

Suchergebnisse filtern